3/7/2023 0 Comments Nodus finance![]() ![]() The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in in vivo models as well as candidate nomination. Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors. Nodus Oncology is a biotech company developing first and best-in-class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Mary-Jane Elliott, Lindsey Neville, Davide Nodus Oncology The development activities will be transferred from Basilea to Nodus Oncology’s drug discovery partner, the Lead Discovery Center (LDC) to accelerate clinical candidate selection.įor more information about Nodus Oncology, please contact: ![]() PARG is a key enzyme in the repair of DNA damage and essential for tumour cells to grow. Nodus secures worldwide development and commercialization rights to Basilea’s PARG inhibitor (PARGi) programme – currently at the discovery stage - which has the potential to be a best-in-class treatment for molecularly defined patient sub-groups. Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programmeĪcquisition enable s Nodus Oncology to continue build ing its portfolio of first and best-in-class molecules inhibiting novel DNA damage response targets (DDR)Įdinburgh, Scotland, 8 September 2022 – Nodus Oncology (“Nodus” or “the Company”), a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, is pleased to announce the completion of an Asset Purchase Agreement (APA) for Basilea Pharmaceutica’s (“Basilea”, SIX: BSLN) novel poly(ADP-ribose) glycohydrolase (PARG) inhibitor discovery programme.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |